Business News • PR NewsWire • Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

TARRYTOWN, N.Y. and BRIDGEWATER, N.J., June 4, 2017 /PRNewswire/ -- Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive preliminary...

View More : http://www.prnewswire.com/news-releases/regeneron-and-sanofi-present-positive-study-results-for-investigational-pd-1-ant...

Releted News by prnewswire

Honda Sweeps Opening Race in Detroit

Acura Wins in the Motor City

Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

ANA Systems elige a IBS Software como socio tecnológico estratégico